260 related articles for article (PubMed ID: 32156525)
1. Effect of fluoride on osteocyte-driven osteoclastic differentiation.
Jiang N; Guo F; Xu W; Zhang Z; Jin H; Shi L; Zhang X; Gao J; Xu H
Toxicology; 2020 Apr; 436():152429. PubMed ID: 32156525
[TBL] [Abstract][Full Text] [Related]
2. PTH (1-34) affects bone turnover governed by osteocytes exposed to fluoride.
Yu X; Yu H; Jiang N; Zhang X; Zhang M; Xu H
Toxicol Lett; 2018 May; 288():25-34. PubMed ID: 29447955
[TBL] [Abstract][Full Text] [Related]
3. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
Allison H; Holdsworth G; McNamara LM
BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
5. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.
Saini V; Marengi DA; Barry KJ; Fulzele KS; Heiden E; Liu X; Dedic C; Maeda A; Lotinun S; Baron R; Pajevic PD
J Biol Chem; 2013 Jul; 288(28):20122-34. PubMed ID: 23729679
[TBL] [Abstract][Full Text] [Related]
7. Different Effects of Fluoride Exposure on the Three Major Bone Cell Types.
Jiang N; Guo F; Sun B; Zhang X; Xu H
Biol Trace Elem Res; 2020 Jan; 193(1):226-233. PubMed ID: 30877522
[TBL] [Abstract][Full Text] [Related]
8. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
9. Irradiation-induced osteocyte damage promotes HMGB1-mediated osteoclastogenesis in vitro.
He F; Bai J; Wang J; Zhai J; Tong L; Zhu G
J Cell Physiol; 2019 Aug; 234(10):17314-17325. PubMed ID: 30786022
[TBL] [Abstract][Full Text] [Related]
10. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
11. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
12. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
13. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
14. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
15. Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity.
Li B; Lu D; Chen Y; Zhao M; Zuo L
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110777
[TBL] [Abstract][Full Text] [Related]
16. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
17. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
18. Role of inhibition of osteogenesis function by Sema4D/Plexin-B1 signaling pathway in skeletal fluorosis in vitro.
Liu XL; Song J; Liu KJ; Wang WP; Xu C; Zhang YZ; Liu Y
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):712-715. PubMed ID: 26489627
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
20. Artesunate inhibits osteoclastogenesis through the miR-503/RANK axis.
Huang MZ; Zhuang Y; Ning X; Zhang H; Shen ZM; Shang XW
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32542308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
